Clinical trials: Single Dose
Healthy
Study of an Extended Release (ER) Tablet, Single and Repeated Dosing
The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the body).
- Trial name
- NCT00689039
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Adult Male and Female Volunteers
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
- Trial name
- NCT04341077
- Testing
- SHR3162
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers
Study to determine the pharmacokinetic properties of 200 mg (2 x 100 mg tablets once daily) and 300 mg (3 x 100 mg tablets once daily) Nevirapine extended release formulations and to estimate relative bioavailability of these…
- Trial name
- NCT02184312
- Testing
- Nevirapine XR low dose, Nevirapine XR medium dose, Nevirapine XR high dose
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Phase Ph+ Chronic Myeloid Leukemia
Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects. The main efficacy is checked by MMR rate by 12 months from IP treatment.
- Trial name
- NCT06665412
- Testing
- Radotinib Hydrochloride
- Where
- 2 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Healthy
Study of ESBA105 Eye Drops in Healthy Subjects
Objectives: To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers.
- Trial name
- NCT00671619
- Testing
- ESBA105
- Where
- Switzerland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ESBATech AG
Arthritis, Rheumatoid
Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)
This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis
- Trial name
- NCT00256919
- Testing
- GW856553
- Where
- 17 sites in Bulgaria, Germany and 3 more
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Healthy
Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults
The purpose of this study is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants.
- Trial name
- NCT04590430
- Testing
- HFB30132A
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HiFiBiO Therapeutics
Healthy
Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects
Safety and pharmacokinetics after oral single rising doses of BIIB 722 CL
- Trial name
- NCT02227030
- Testing
- BIIB 722 CL solution, BIIB 722 CL tablet
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Adult Participants
Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.
- Trial name
- NCT06429930
- Testing
- L608 Liposomal inhalation suspension
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Influenza, Human
A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers
This is a study in healthy adult volunteers to assess the bioequivalence of over-encapsulated oseltamivir capsules to commercially available oseltamivir capsules. Both formulations will be administered in the fasting state.
- Trial name
- NCT01258530
- Testing
- over-encapsulated oseltamivir, oseltamivir
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult Subjects
The purpose of this study is to determine the safety and tolerability, and to evaluate the pharmacokinetic characteristics of Mianhuahua Flavonoids Tablets after oral administration in healthy adult subjects.
- Trial name
- NCT02622230
- Testing
- Mianhuahua Flavonoids Tablets
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xinjiang Uygur Pharmaceutical Co., Ltd.
Invasive Aspergillosis
Evaluation of Immediate Release Tablet
Single dose comparison of liquid and solid formulation, followed by study of effect of high fat breakfast. Evaluation of multiple dose pharmacokinetics and tolerability
- Trial name
- NCT02808741
- Testing
- F901318 SDD, F901318 IR, F901318 IR Fasting
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Recessive Dystrophic Epidermolysis Bullosa
A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Protocol PTR-01-001 is a Phase 1/2 study of PTR-01. The study is divided into an up to 4-week Screening Period, a 10-week Treatment Period and an 8-week Follow-up Period.
- Trial name
- PTR-01-001 (NCT03752905)
- Testing
- PTR-01, Normal saline
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Phoenix Tissue Repair, Inc.
Migraine in Children, Migraine
A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab
The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.
- Trial name
- NCT04537429
- Testing
- Eptinezumab
- Where
- 9 sites in United States
- Volunteers
- 28 people
- Sponsor
- H. Lundbeck A/S
Healthy Subjects
A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
The primary purpose of this first-in-man study is to investigate whether AC-084 is safe and well-tolerated when orally administered at single- and multiple-ascending dose to healthy adults
- Trial name
- NCT02905253
- Testing
- AC-084
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Acromegaly
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of…
- Trial name
- NCT00234572
- Testing
- Lanreotide (Autogel formulation)
- Where
- 29 sites in United States, Czechia and 6 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
Type 2 Diabetes Mellitus
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition
The purpose of the clinical trail is to evaluate the pharmacokinetics and safety/tolerability after oral administration of CKD-387 and D635 under fed condition in healthy adults.
- Trial name
- NCT03849339
- Testing
- CKD-387, D635
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib while it is still in the body. Healthy participants will get one dose of tucatinib by mouth.
- Trial name
- NCT03758339
- Testing
- tucatinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cascadian Therapeutics Inc.
Treatment of Acute Zika Virus Infection
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans
Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector that transmits Dengue virus, Aedes aegypti.
- Trial name
- NCT03443830
- Testing
- Tyzivumab
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tychan Pte Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
The main goal of this pharmacokinetic study in healthy volunteers is to evaluate the potential effect of cyclosporine (probe inhibitor of P glycoprotein [P-gp] and breast cancer resistance protein [BCRP] transporters) on CHF6001…
- Trial name
- DDI2 (NCT06892756)
- Testing
- CHF6001 dry powder inhaler (DPI), Cyclosporine, CHF6001 DPI
- Where
- Bulgaria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.